Biotech
Mar 26, 2008
Cardiome Pharma says FDA delay hasn't impacted interest from strategic review
“The FDA delay has affected our strategy more than external people's strategy looking at Cardiome”
Cardiome Pharma Corp. said while the U.S. Food and Drug Administration continues to drag its feet on a decision regarding its new drug application for the heart treatment Kynapid, it doesn't believe the delay ... via Canadian Business Magazine
Posted by roboblogger
Full Story: Canadian Business Magazine
Complete Coverage: 3 stories
- The Globe and Mail - Cardiome Pharma loss widens
- 680News - Cardiome Pharma says FDA delay hasn't impacted interest from strategic review
- The Toronto Star - Cardiome Pharma widens annual loss
Related Topix
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Bird Rock Bandits Get Day In Court | 54 min | Aslueth | 27 |
| KUSI Reporter Rod Luck Arrested | 3 hr | Earl Sanders | 61 |
| Holocaust survivor runs for melanoma awareness | 5 hr | Hillary | 7 |
| Lawsuits filed over Lipitor side effects (from Jun '06) | 7 hr | Leap for Pat... | 433 |
| Surf wars: a killing that made waves | 8 hr | dude | 1 |
| 335 Eli Lilly employees accept buyout offer fro... | 8 hr | White Pride | 3 |
| Pfizer to close Terre Haute plant | 9 hr | tinman | 4 |
